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Letter to Editor
Probing newer possibilities for detecting drug resistance in malaria
Sir,
Malaria is a major public health disease attributed to 214 million of new cases and more than 4 lakh deaths in 2015 [1]. African countries have the highest incidence 
followed by Southeast Asian (SEA) countries, among which India 
has the maximum disease burden. However, smear microscopy 
and use of rapid diagnostic test have strengthened early diagnosis 
and timely initiation of treatment. Emerging drug resistance such 
as chloroquine resistance in Plasmodium vivax and the evolving 
tolerance in Plasmodium falciparum to artemisinin combination 
therapy (ACT) has further superadded to the existing problems. 
According to the World Health Organization (WHO), Thai-
Cambodian border region has been the focus for the emerging 
artemisinin resistance due to several factors [1]. P. falciparum has 
become resistant to almost all available antimalarial medicines 
in this region. Charles Woodrow et al. have reviewed in detail 
the expanding artemisinin resistance in SEA which is leading 
to failure of all the artemisinin-based combinations [2]. Rapid 
dissemination of resistant parasite to the other parts of this 
subregion as well the other parts of the world is the major threat 
at present [3]. India is at the highest risk for the acquisition of this 
entity due to the close approximation of its territorial border with 
that Myanmar, Bangladesh and the existence of freely moving 
livelihood across these boundaries [4].
WHO has defined “artemisinin resistance” as delayed parasite 
clearance following treatment with either artesunate monotherapy 
or ACT [5]. Such resistance is regarded as partial resistance which 
may be due to artemisinin resistance or resistance to partner drug in 
ACT. Routine monitoring of the ACT treatment failure rates based 
on the presence of parasitemia on day 3 and treatment failure rate 
at 28 or 42 days follow-up is essential to make a timely decision 
for changing the drug policy [5]. Delayed parasite clearance has 
been shown to be associated with mutations in the Kelch13 (K13) 
propeller region by both in vitro and in vivo studies. Delayed 
parasite clearance along with K13 mutations in a single patient 
will be suggestive of confirmed artemisinin resistance. A total of 
186 K13 alleles, including 108 non-synonymous mutations, have 
been reported from different parts of the world. The presence of 
mutants does not lead to resistance in all, as most of the mutants 
represent “passer-by” with no alteration in parasite clearance. 
However, recent studies have documented four mutants (493H, 
539T, 543T, and 580Y) as confirmed K13 propeller mutations 
from both in vivo and in-vitro experiments [5]. Recently, the 
MalariaGEN P. falciparum Community Project has shown that 
the K13 mutations responsible for resistance were present in low 
frequency in the African region when compared to SEA region. 
Most of the African K13 mutations originated locally when 
compared to the SEA region which showed a strong evolutionary 
spread and selection [6]. Therefore, detection of K13 mutation 
in the SEA region is important to detect resistance and thereby 
enforce newer interventions to prevent the further spread of 
resistance. 
A disease similar to malaria is tuberculosis (TB) with a 
worldwide burden of 9.6 million cases attributing to around 
1.5 million death annually [7]. Worldwide TB also bears a similar 
threat of emerging multidrug resistance TB (MDR) and even 
extensive drug resistance. Techniques like line probe assay (LPA) 
are capable of detecting the mutations responsible for resistance. 
Genotype® MTBDRsl assay which is capable of detecting 
resistance even in the second line antitubercular drugs has been 
approved by WHO before initiating therapy for MDR cases [7]. 
LPA has been utilized in many fields like detection of drug 
resistance in TB, genotyping of hepatitis C virus, and others [8]. 
LPA is suitable for use at reference laboratories, or at laboratories 
where molecular testing facilities are available.
K13 mutation detection for artemisinin resistance requires 
PCR and sequencing which are costly, time consuming and 
not feasible at all health-care facilities. Therefore, the need of 
the hour is to develop an innovative platform like the LPAs for 
the detecting the mutations responsible for drug resistance in 
P. falciparum and other Plasmodium spp. LPA will be a rapid and 
cost-effective technique with limited equipment need. Based on 
the resistance patterns obtained by LPA, an effective alternative 
therapy can be decided. The use of this technique will also 
enhance the implementation of stewardship policy for the right 
use of antimalarial similar to that of antibiotics. 
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